A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer
Alberto Servetto(University of Naples Federico II), Luigi Formisano(University of Naples Federico II), Grazia Arpino(University of Naples Federico II), Roberto Bianco(Federico II University Hospital), Mario Giuliano(Regione Campania), Sabino De Placido, Pietro De Placido(University of Naples Federico II), Fabiana Napolitano(Harold C. Simmons Comprehensive Cancer Center), Carmine De Angelis(Baylor College of Medicine)
Cited by 14
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282